Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings ... s revenue estimates three times over the last two years. Looking at Incyte’s peers in the biotechnology ...

Below is Validea's guru fundamental report for INCYTE CORP (INCY). Of the 22 guru strategies we follow, INCY rates highest using our Multi-Factor Investor model based on the published strategy of ...

I first met Wincy Ong in the buzzing world of advertising and PR, a place where creativity and storytelling intertwine with the art of persuasion. Back then, we were just two professionals navigating ...

Incyte (INCY) reported $1.18 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 16.3%. EPS of $1.43 for the same period compares to $1.06 a year ago.

Incyte (INCY) came out with quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.06 per share a year ago. These figures ...

Shares of Incyte (NASDAQ:INCY) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. The biotech company reported that Q4 revenue rose 16% year-over-year to $1 ...